Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2016; 22(4): 1650-1663
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1650
Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon
Sara Belga, Karen Elizabeth Doucette
Sara Belga, Karen Elizabeth Doucette, Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2G3, Canada
Author contributions: Belga S and Doucette KE contributed equally to this work, including review of the literature, writing and editing of the manuscript.
Conflict-of-interest statement: Belga S has no conflict of interest to declare; Doucette KE has received speaker honoraria from Bristol-Myers Squibb and Gilead and has received research support from Bristol-Myers Squibb, Gilead, Merck, AbbVie.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Karen Elizabeth Doucette, MD, MSc, Division of Infectious Diseases, Department of Medicine, University of Alberta, 11350 83 Avenue, Clinical Sciences Building 1-139, Edmonton, Alberta T6G 2G3, Canada.
Telephone: +1-780-4927686 Fax: +1-780-4928050
Received: July 31, 2015
Peer-review started: July 31, 2015
First decision: August 31, 2015
Revised: September 20, 2015
Accepted: November 24, 2015
Article in press: November 24, 2015
Published online: January 28, 2016
Core Tip

Core tip: Direct acting antiviral (DAA) therapy has the potential to eliminate hepatitis C virus (HCV) from the population of organ transplant candidates and recipients and thereby the negative impact of HCV on outcomes. Among non-hepatic organ transplant patients, the biggest barriers currently are limited safety and efficacy data in this population, particularly in those with advanced renal disease, and global variability of access and reimbursement for DAAs. Future research is needed to better assess safety, efficacy and impact of DAA therapy in non-hepatic solid organ transplant, as well as to explore the safety of using HCV infected donors, with prophylactic therapy, to expand the donor pool.